Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development - (III) A Randomized Trial with Interferon Beta-1a Products

This study illustrates potential methodologies for evaluating PD biomarkers and an approach to address information gaps when limited information is publicly available for one or more PD biomarkers.PMID:36324229 | DOI:10.1002/cpt.2784

Source: Clinical Pharmacology and Therapeutics - November 3, 2022 Category: Drugs & Pharmacology Authors: Jeffry Florian Victoria Gershuny Qin Sun Sarah J Schrieber Murali K Matta Anthony Hazel Morasa Sheikhy James L Weaver Paula Hyland Cheng-Hui Hsiao Giri Vegesna Ryan DePalma Aanchal Shah Kristin Prentice Carlos Sanabria Yow-Ming Wang David G Strauss Source Type: research